BioCardia Inc logo

BCDA - BioCardia Inc Share Price

$3.93 0.0  0.8%

Last Trade - 02/03/21

Sector
Healthcare
Size
Micro Cap
Market Cap £40.5m
Enterprise Value £35.6m
Revenue £226k
Position in Universe 5444th / 6633
Bullish
Bearish
Unlock BCDA Revenue
Momentum
Relative Strength (%)
1m -6.04%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.43 0.90 0.58 0.48 0.63 0.71 0.12 0.50 +10.7%
+1,132
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,BioCardia Inc revenues decreased 80% to $99K. Net lossincreased 7% to $12M. Revenues reflect Collaborationagreement revenue decrease of 76% to $86K, Net productrevenue decrease of 91% to $13K. Higher net loss reflectsResearch and development - Balancing val increase of 14% to$6.4M (expense), Stock-based Compensation in R&D increaseof 38% to $1.1M (expense), Selling.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BCDA Revenue Unlock BCDA Revenue

Net Income

BCDA Net Income Unlock BCDA Revenue

Normalised EPS

BCDA Normalised EPS Unlock BCDA Revenue

PE Ratio Range

BCDA PE Ratio Range Unlock BCDA Revenue

Dividend Yield Range

BCDA Dividend Yield Range Unlock BCDA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BCDA EPS Forecasts Unlock BCDA Revenue
Profile Summary

BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 12, 1994
Public Since November 13, 1996
No. of Shareholders: 201
No. of Employees: 20
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 14,467,630
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BCDA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BCDA
Upcoming Events for BCDA
Frequently Asked Questions for BioCardia Inc
What is the BioCardia Inc share price?

As of 02/03/21, shares in BioCardia Inc are trading at $3.93, giving the company a market capitalisation of £40.5m. This share price information is delayed by 15 minutes.

How has the BioCardia Inc share price performed this year?

Shares in BioCardia Inc are currently trading at $3.93 and the price has moved by 6.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioCardia Inc price has moved by -13.83% over the past year.

What are the analyst and broker recommendations for BioCardia Inc?

There are no analysts currently covering BioCardia Inc.

When will BioCardia Inc next release its financial results?

BioCardia Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the BioCardia Inc dividend yield?

BioCardia Inc does not currently pay a dividend.

Does BioCardia Inc pay a dividend?

BioCardia Inc does not currently pay a dividend.

When does BioCardia Inc next pay dividends?

BioCardia Inc does not currently pay a dividend.

How do I buy BioCardia Inc shares?

To buy shares in BioCardia Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioCardia Inc?

Shares in BioCardia Inc are currently trading at $3.93, giving the company a market capitalisation of £40.5m.

Where are BioCardia Inc shares listed? Where are BioCardia Inc shares listed?

Here are the trading details for BioCardia Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BCDA
What kind of share is BioCardia Inc?

Based on an overall assessment of its quality, value and momentum, BioCardia Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioCardia Inc share price forecast 2021?

Shares in BioCardia Inc are currently priced at $3.93. At that level they are trading at 0.23% discount to the analyst consensus target price of 0.00.

Analysts covering BioCardia Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.617 for the next financial year.

How can I tell whether the BioCardia Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioCardia Inc. Over the past six months, the relative strength of its shares against the market has been 51.74%. At the current price of $3.93, shares in BioCardia Inc are trading at 28.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioCardia Inc PE Ratio?

We were not able to find PE ratio data for BioCardia Inc.

Who are the key directors of BioCardia Inc?

BioCardia Inc's management team is headed by:

Peter Altman - PRE
Simon Stertzer - CHM
Fernando Fernandez - IND
Richard Krasno - IND
David McClung - CFO
Phil Pesta - VOP
Jim Allen - IND
Andrew Blank - IND
Krisztina Zsebo - DRC
Sujith Shetty - OTH
Who are the major shareholders of BioCardia Inc?

Here are the top five shareholders of BioCardia Inc based on the size of their shareholding:

Frost Gamma Investments Trust Corporation
Percentage owned: 10.66% (1.54m shares)
Stertzer (Simon H) Individual Investor
Percentage owned: 8.61% (1.25m shares)
Peters (Gerald P) Individual Investor
Percentage owned: 6.73% (974k shares)
Roumell Opportunistic Value Fund Mutual Fund
Percentage owned: 5.56% (805k shares)
Stertzer Family Trust Corporation
Percentage owned: 4.9% (710k shares)
Similar to BCDA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.